Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
Ha, bond-related except for Romick and Ahlsten and FJames and Ivy S&T guys and maybe a very few others. I guess I better ditch Tillinghast now that M* has again downgraded FLPSX. Wait, what? M* shows 4*. Ah, 3* ... for last 3y.
In my gradually expanding experience, buying 5* funds in fund categories (not including sector funds, where one has to get the sector plus the manager right), adds a bit to performance. Must admit that the health care sector seems a lock, and I think that health biotech will prove to have been a "lock" for anyone with a ten year horizon.
Comments